Hycor Biomedical Applies CE Mark to IVD Allergy Instrument: NOVEOS(TM)
GARDEN GROVE, California, Jan. 4, 2018 /PRNewswire/ — Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that it has applied the CE mark to its allergy testing system, NOVEOS((TM)), along with an initial menu of Total IgE and over one hundred Specific IgE allergen reagents.
NOVEOS offers several breakthrough features including:
— Smaller sample requirements: Only 4µL of patient sample volume is
required which can be especially important in pediatric and geriatric
sampling where it may be more difficult to retrieve larger samples.
— True walk away capability: On-board reagents supply sufficient capacity
for up to 8 hours of continuous testing. This eliminates the need to
continuously replenish materials throughout a typical work day. It
allows maximum walk away time for laboratory technicians by allowing up
to 75 tests per specific allergen and up to 140 allergens on the system
at any time.
— Use of standardized extracts: Many of the unrefined extracts that are
used in skin-prick testing and competitive allergy assays generate less
reliable patient results due to their complexity. As the allergen
industry moves to more highly enriched or standardized extracts, the
NOVEOS system has incorporated these materials to provide more
consistent and accurate results.
“We are excited to bring NOVEOS to market in the EU,” said Dr. Fei Li, President and Chief Executive Officer at Hycor. “These breakthrough features underscore Hycor’s commitment to drive immunodiagnostics into the future by offering the first new highly-automated allergy platform technology in a generation.”
“A new lab testing option for allergies with these breakthrough features is very welcome in the medical community,” said Professor Harald Renz, Director and Chairman of Laboratory Medicine and Pathobiochemistry at Philipps University, Marburg, Germany and Past President of the German Society of Allergology and Clinical Immunology. “Specifically, the lower sample size requirement, which is 1/10(th) of the sample size required by most labs today, has the potential to redefine the experience for both pediatric and elderly patients and for labs.”
NOVEOS is Hycor’s latest allergy testing instrument to be introduced to the EU market. Hycor will be seeking 510(k) clearance from the Food and Drug Administration in the United States in the future.
About Hycor Biomedical
Founded in 1981, Hycor is a global manufacturer and marketer of in vitro diagnostic products. Since its founding, Hycor has expanded its presence into allergy and autoimmune products used in clinical laboratories, hospitals and doctors’ offices worldwide. Hycor recently launched NOVEOS((TM)) which adds to the Company’s existing line of products including HYTEC(®) and AUTOSTAT(®) brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com [http://www.hycorbiomedical.com/].
https://mma.prnewswire.com/media/623514/Hycor_Biomedical_Logo.jpg [https://mma.prnewswire.com/media/623514/Hycor_Biomedical_Logo.jpg ]
Photo – https://mma.prnewswire.com/media/623497/Hycor_Biomedical_NOVEOS.jpg [https://mma.prnewswire.com/media/623497/Hycor_Biomedical_NOVEOS.jpg]
Logo – https://mma.prnewswire.com/media/623514/Hycor_Biomedical_Logo.jpg [https://mma.prnewswire.com/media/623514/Hycor_Biomedical_Logo.jpg]
CONTACT: Media Contact: Elizabeth Fatone, inVentiv Health, Liz.Fatone@inventivhealth.com, Ph: 310-963-5221
Web site: http://www.HYCORbiomedical.com/